AddThis

Taro receives FDA approval for skin cancer generic

Related Content

No related items were found.

HAWTHORNE, N.Y. The Food and Drug Administration has approved Taro Pharmaceutical Industries’ generic version of a drug for treating skin cancer, Taro announced Monday.

The FDA approved Taro’s fluorouracil cream in the 5% strength. The drug is used to treat superficial basal cell carcinoma and multiple actinic or solar keratosis.

Fluorouracil is a generic version of Valeant Pharmaceuticals’ Efudex, which had sales of $70 million in 2009, according to industry sources.

© 2014 Drug Store News. All Rights Reserved.